Seegene Advances Reproductive Health Testing with Comprehensive PCR Approach in Global Study

Seegene's Innovative Approach to Reproductive Tract Infection Testing

In a significant advancement for reproductive health diagnostics, Seegene Inc. has proposed a comprehensive syndromic polymerase chain reaction (PCR) testing approach aimed at effectively identifying reproductive tract infections (RTIs). Announced on July 27, 2026, the initiative leverages the data collected through the Global Million Clinical Study (GMCS) to enhance screening for sexually transmitted infections (STIs) and human papillomavirus (HPV).

The impetus behind this innovative testing approach arises from the increasing recognition of HPV as a principal cause of cervical cancer, particularly the high-risk genotypes HPV-16 and HPV-18. Accurate identification of these genotypes is critical for patient management, as it influences screening and follow-up strategies. Seegene’s new method not only screens for HPV but also tests for a comprehensive panel of STIs, incorporating pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae, which often present overlapping symptoms.

A recent analysis conducted using StAgora™, Seegene’s real-time data analytics platform, reviewed around 60,000 co-testing results over a span of 42 months. This analysis revealed notable findings: STIs were detected in 82% of HPV-positive cases, while HPV was found in 46% of STI-positive cases. Moreover, both HPV and STI pathogens were co-detected in 71% of positive cases, highlighting the potential of concurrent testing to unveil important aspects of an individual's reproductive health status.

Identifying co-infections can especially aid in managing reproductive health, particularly for individuals facing infertility or preparing for pregnancy. With this dual-testing approach, healthcare providers can offer more personalized treatment plans, taking into account the complexities of co-existing infections and patient history.

The GMCS aims to establish standards for PCR testing by gathering real-world clinical data from diverse healthcare settings worldwide. Seegene is committed to validating the clinical utility of its comprehensive HPV/STI testing methodology, addressing the need for greater accuracy in distinguishing various pathogens that can cause similar clinical symptoms.

Asymptomatic infections, which are common in STIs, pose significant challenges for healthcare providers attempting to reduce transmission rates. By offering a comprehensive testing platform, Seegene not only enhances the chance of identifying these unrecognized infections but also supports the overall goal of improving public health outcomes.

The significance of this initiative will be further discussed at the upcoming Association for Diagnostics Laboratory Medicine (ADLM 2026) symposium. As Seegene strives to broaden access to its molecular diagnostics technologies through partnerships and initiatives like the Technology Sharing Initiative, it emphasizes the importance of being prepared for infectious diseases and maintaining high standards in diagnostic testing.

In closing, Seegene’s comprehensive approach represents a promising evolution in reproductive and sexual health diagnostics, integrating advanced molecular technologies to improve patient care and outcomes worldwide. As the GMCS progresses, the implications for standardizing testing practices and enhancing public health policies could be profound, paving the way for improved understanding and management of reproductive tract infections.